Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Link opens in a new tab
Search content at UTMB Health Research Expert Profiles
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Sirolimus use and cancer incidence among US kidney transplant recipients
E. L. Yanik
, S. K. Gustafson
, B. L. Kasiske
,
A. K. Israni
, J. J. Snyder
, G. P. Hess
, E. A. Engels
, D. L. Segev
Research output
:
Contribution to journal
›
Article
›
peer-review
59
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Sirolimus use and cancer incidence among US kidney transplant recipients'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cancer Incidence
100%
Kidney Transplant Recipients
100%
Sirolimus
100%
Confidence Interval
23%
Hazard Ratio
23%
Prostate Cancer Risk
15%
Kidney Transplantation
15%
Cancer Registry
15%
Transplant Registry
15%
Pharmacy Claims
15%
Demographic Characteristics
7%
Prostate Cancer
7%
Cancer Risk
7%
In Cancer
7%
Clinical Characteristics
7%
Prostate Cancer Screening
7%
Non-melanoma Skin Cancer
7%
Cox Regression
7%
Kidney Transplant
7%
Immunosuppressive Therapy
7%
Population-based Cancer Registry
7%
Post-transplant Cancer
7%
Exposed Time
7%
Anticarcinogenic Properties
7%
Medicine and Dentistry
Cancer Incidence
100%
Kidney Graft
100%
Rapamycin
100%
Prostate Cancer
23%
Hazard Ratio
23%
Cancer Registry
23%
Kidney Transplantation
15%
Malignant Neoplasm
7%
Cancer
7%
Cancer Risk
7%
Immunosuppressive Treatment
7%
Gene Linkage
7%
Non Melanoma Skin Cancer
7%
Proportional Hazards Model
7%
Immunosuppressant
7%
Prostate Cancer Diagnosis
7%
Pharmacology, Toxicology and Pharmaceutical Science
Rapamycin
100%
Cancer Incidence
100%
Prostate Cancer
30%
Cancer Registry
23%
Immunosuppressive Agent
15%
Malignant Neoplasm
7%
Non Melanoma Skin Cancer
7%